25th Annual Cancer Progress Conference  
March 4 - 5, 2014  
New York

AGENDA

Tuesday, March 4, 2014

7:00 - 8:00am  Registration and Continental Breakfast

8:00 - 8:15am   Opening Remarks
•  Jeff Bockman, PhD, VP, Defined Health

8:15 - 8:45am   Keynote Address
•  Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline

8:45 - 10:00am  Taking Immunotherapy Seriously: New Targets and Combinations  
Moderator:
•  Axel Hoos, MD, PhD, VP, Oncology Research and Development, GlaxoSmithKline
Panelists:
•  Jeff Bockman, PhD, VP, Defined Health  
•  Ira Mellman, PhD, VP, Research Oncology, Genentech  
•  Galit Rotman, PhD, Chief Scientist of Therapeutics, Compugen  
•  Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center  
•  Lauren V. Wood, MD, Senior Clinical Investigator, Vaccine Branch, National Cancer Institute

10:00 - 10:30am  Networking Break

10:30 - 11:45am  Brain Cancer - Tackling the Intractable: Novel Targets and Approaches  
Moderator:
•  Minesh P. Mehta, MD, Medical Director, Maryland Proton Treatment Center, University of Maryland
Panelists:
• Lauren Abrey, MD, Oncology Development Site Head, F. Hoffmann-La Roche Inc.
• Thomas Davis, MD, CMO and SVP Clinical Development, Celldex Therapeutics
• H. Ian Robins, MD, PhD, Faculty, University of Wisconsin School of Medicine and Public Health
• Eric Rowinsky, MD, Chief Medical Officer, Head of Research & Development, Stemline Therapeutics

11:45 - 1:00pm  Big Data and Cancer: Transforming Patient Care by Turning Data into Decisions

Moderator:

• Colin Hill, Chief Executive Officer, President & Chairman, GNS Healthcare

Panelists:

• Alexis Borisy, Entrepreneur in Residence, Third Rock Ventures
• Joel Dudley, PhD, Director of Biomedical Informatics and Assistant Professor of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai
• Brian Leyland-Jones, MD, VP, Molecular and Experimental Medicine, Avera Health
• Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
• Timothy J. Thompson, CEO, Intervention Insights

1:00 - 2:15pm  Networking Luncheon

2:15 - 3:30pm  Evidentiary Standards for Diagnostics: When does a Biomarker Become a Diagnostic for Cancer Treatment?

Moderator:

• Steven Averbuch, MD, VP, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company

Panelists:

• Anna Barker, PhD, Director, Transformative Healthcare Networks, Arizona State University
• Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
• Steven Gutman, MD, Strategic Advisor, Myraqa
• Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna
• Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
• Kim Zerba, PhD, Group Director, Global Biometric Sciences, Bristol-Myers Squibb

3:30 - 4:00pm  Networking Break

4:00 - 5:15pm  Oncology R&D: ROI and the New Expectations

Moderator:

• Steve Heller, Principal, OncStrat LLC

Panelists:

• Walter Capone, President, The Multiple Myeloma Research Foundation
• Jeanne Farrell, PhD, Business Development Director, Icahn School of Medicine at Mount Sinai
• Debasish Roychowdhury, MD, President, Nirvan Consultants, LLC
• Mark J. Simon, Advisor, Torreya Partners LLC

5:15 - 6:30pm  New Treatment Options for Prostate Cancer

Moderator:

• Jeremy P. Goldberg, President, JPG Healthcare LLC

Panelists:

• Richard Brian Gaynor, MD, VP, Product Development/Medical Affairs, Eli Lilly and Company
• Marco Gottardis, Ph D, VP and Prostate Cancer Disease Area Stronghold Leader, Oncology Therapeutic Area, Janssen Research & Development, LLC
• Richard Heyman, CEO, Seragon (ex-CEO Aragon)
• Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
• Marianne Sadar, PhD, Distinguished Scientist, BC Cancer Agency. Professor of Pathology and Laboratory Medicine, University of British Columbia

6:30 - 8:30pm  Cancer Progress 2014 Reception
Wednesday, March 5, 2014

7:00 - 8:00am  Continental Breakfast

8:00 - 8:15am  Opening Remarks

•   Mike Rice, MS, MBA, Senior Consultant, Defined Health

8:15 - 9:15am  Keynote Address - A Trialogue: Valuing Value in Oncology

Moderator:

•   Ed Saltzman, President, Defined Health

Panelists:

•   Peter Bach, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center
•   Professor David Haslam, CBE, FRCGP, FRCP, FFPH Chairman, NICE
•   Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 2013-2014 President, ASCO

9:15 - 10:30am  Antibody-Drug Conjugates:
Supercharging the Blockbuster Antibody Class

Moderator:

•   Jeff Bockman, PhD, VP, Defined Health

Panelists:

•   Robert Cohen, MD, Calico Life Sciences
•   Jonathan Drachman, MD, SVP, Research and Translational Medicine, Seattle Genetics
•   Hans-Peter Gerber, PhD, VP, BioConjugate Discovery & Development, Oncology Research, Pfizer
•   John Lambert, PhD, EVP, Research & Development & Chief Scientific Officer, ImmunoGen, Inc.
•   Peter Kiener, Ph D, Chief Scientific Officer, Ambrx, Inc.

10:30 - 10:45am  Networking Break

10:45 - 12:00pm  Cancer Gene & Cell Therapy:
Expanding Therapeutic Options With Living Drugs

Moderator:
• Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

• Estuardo Aguilar-Cordova, PhD, Chief Executive Officer Advantagene, Inc.
• Renier J. Brentjens, MD, PhD, Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center
• Nori Kasahara, M.D., Ph.D., Director, CURE Vector Core Facility JCCC Vector Shared Resources, Professor, Department of Medicine, Molecular & Medical Pharmacology, UCLA
• Angela Shen, MD, MBA, Global Clinical Program Head, CTL019, Oncology Clinical Development, Novartis Pharmaceuticals Corp

12:00 - 1:15pm Intrinsic and Acquired Resistance in Cancer: Getting Smarter About Combinations and Sequencing

Moderator:

• Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

Panelists:

• Jeffrey A. Engelman, MD, PhD, Director of Thoracic Oncology and Director of Molecular Therapeutics, Massachusetts General Hospital Cancer Center
• Greg Plowman, MD, PhD, VP, Oncology Research Eli Lilly and Company
• David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan Kettering Cancer Center

1:15 - 2:30pm Networking Luncheon

2:30 - 3:45pm Challenging Established Paradigms in Cancer

Moderator:

• Sol J. Barer, PhD, SJBerer Consulting LLC

Panelists:

• Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
• Giulio Draetta, MD, PhD, Director, Institute for Applied Cancer Science, Professor, Genomic Medicine, MD Anderson Cancer Center
• Tak Mak, PhD, University Professor, Ontario Cancer Institute, University of Toronto
Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

3:45 - 4:00pm  Networking Break

4:00 - 5:15pm  Translational Oncology: How to Better Transform Targets into Relevant Drugs for Patients

Moderators:

- Jeffrey M. Bockman, PhD, VP, Defined Health
- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Joseph Beechem, PhD, SVP, Research and Development, NanoString Technologies
- Pamela Carroll, PhD, VP, Oncology, Innovation Center in Boston, Janssen Research & Development
- Rajesh Chopra, MD, PhD, Corporate VP, Translational and Early Drug Development, Celgene Corporation
- Victoria Richon, PhD, VP and Head of Cancer Research, Discovery and Early Development, Sanofi
- Spiro G. Rombotis, President & CEO, Cyclacel Pharmaceuticals, Inc.

5:15pm  Closing Remarks

5:30pm  Cancer Progress 2014 Conference Concludes